<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01868191</url>
  </required_header>
  <id_info>
    <org_study_id>WOE_2013_SB</org_study_id>
    <nct_id>NCT01868191</nct_id>
  </id_info>
  <brief_title>Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD)</brief_title>
  <official_title>Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD)and Diabetic Neuropathy in Subjects With Sensorimotor Diabetic Polyneuropathy: a Double-blind, Randomized, Placebo-controlled Parallel Group Pilot Study Over 12 Months.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diabetes Schwerpunktpraxis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Woerwag Pharma GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Diabetes Schwerpunktpraxis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to assess before, as well as 6 and 12 months following a
      therapy with benfotiamine the influence of therapy on intraepidermal nerve fiber density
      (skin biopsy) and neuropathic symptoms and deficits in people with type 1 or 2 diabetes
      mellitus and diabetic sensomotoric neuropathy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in intraepidermal nerve fiber density</measure>
    <time_frame>6 and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in neuropathic symptoms</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Following questionnaires will be used to assess neuropathic symptoms: modified Toronto Clinical Neuropathy Score and Michigan Neuropathy Screening Instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in neuropathic deficits</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>A score will be calculated at each timepoint using the Michigan Neuropathy Screening Instrument</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Diabetic Neuropathies</condition>
  <arm_group>
    <arm_group_label>Placebo for benfotiamine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for benfotiamine 600 mg/day for the first 3 months followed by 300 mg/day for 9 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benfotiamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with benfotiamine 600 mg/day for 3 months followed by 300 mg/day for 9 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benfotiamine</intervention_name>
    <description>Treatment with 600 mg/day for the first 3 months followed by 300 mg/day for 9 months</description>
    <arm_group_label>Benfotiamine</arm_group_label>
    <other_name>Milgamma protekt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for benfotiamine</intervention_name>
    <description>Treatment with placebo for benfotiamine 600 mg/day for the first 3 months followed by 300 mg/day for 9 months</description>
    <arm_group_label>Placebo for benfotiamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have type 1 or type 2 diabetes mellitus based on the disease diagnostic criteria (WHO)
             classification on ongoing insulin or/and oral antidiabetic therapy with a stable
             regimen for the previous 3 months

          -  Male or female subjects aged between 18 and 75 years, inclusive

          -  Have an HbA1c level ≤ 9.5% without optimizing potential

          -  mTCNS (modified Toronto Clinical Neuropathy Score) ≥ (above or equal to) 6) OR (a
             score on the MNSI (Michigan Neuropathy Screening Instrument)questionnaire of ≥4 or a
             score on the MNSI examination ≥2.5)

          -  Medical history without major pathology (with the exception of type 2 diabetes) as
             judged by the investigator, especially no major peripheral artery disease.

          -  Body mass index (BMI) between 25 and 45kg/m2, both inclusive

        Exclusion Criteria:

          -  Subjects with secondary forms of diabetes such as due to pancreatitis.

          -  Current or previous treatment (less than 6 months) with benfotiamine, B-vitamins,
             vitamin B complex, alpha lipoic acid or actovegin.

          -  Have any contraindications, known allergy, or hypersensitivity to benfotiamine.

          -  Have any contraindications, known allergy, or hypersensitivity to local anesthetics.

          -  Neuropathy by other origin than diabetes.

          -  Other severe pain that might impair the assessment of neuropathic pain.

          -  Treatment with more than one of following: tricyclic antidepressants, serotonin
             norepinephrine reuptake inhibitors, anticonvulsants, class I antiarrhythmics with
             Na-channel inhibition (mexiletine, flecainid, propafenon and others) or neuroleptics
             in patients receiving these drugs for neuropathic pain.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alin O Stirban, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes Schwerpunktpraxis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alin O Stirban, MD, PhD</last_name>
    <phone>+4921314018</phone>
    <phone_ext>486</phone_ext>
    <email>alin.stirban@profil.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Diabetes Schwerpunktpraxis</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helga Zeller-Stefan, MD</last_name>
      <phone>+492011788892</phone>
      <email>helga.zeller@gmx.de</email>
    </contact>
    <investigator>
      <last_name>Alin O Stirban, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Helga Zeller-Stefan, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2013</study_first_submitted>
  <study_first_submitted_qc>May 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2013</study_first_posted>
  <last_update_submitted>May 30, 2013</last_update_submitted>
  <last_update_submitted_qc>May 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Diabetes Schwerpunktpraxis</investigator_affiliation>
    <investigator_full_name>Ovidiu Alin Stirban</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benphothiamine</mesh_term>
    <mesh_term>Thiamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

